New Study Reveals Safety of COVID-19 Vaccination in Early Pregnancy — Evidence from 520,000 Births on Pregnancy and mRNA Vaccines

A study published in JAMA Network Open, using the national registry of France, analyzed 527,564 births and concluded that mRNA vaccination during early pregnancy (0–13 weeks) does not lead to a significant increase in any of the major 75 categories of congenital anomalies. The overall weighted OR was 0.98, and the stillbirth rate was 0.4% in both the vaccinated and unvaccinated groups, showing no difference. This aligns with existing studies from Nordic countries, Canada, and others, further strengthening the evidence of "no teratogenicity." Meanwhile, in the United States, from spring 2025 onwards, administrative messages have become inconsistent, causing confusion in recommendations and access for pregnant women. On social media, there is a mix of relief and intention to utilize the vaccine among healthcare providers, uncertainty among those affected, and some misinformation. Overall, the scientific safety data remains robust, and the practical approach is to verify the latest regional operational and insurance information and engage in shared decision-making with one's primary care physician.